This is a historical account of the origin and accomplishments of the North American Clinical Trials Network (NACTN) for traumatic spinal cord injury (SCI), which was established in 2004 by Christopher Reeve and Robert Grossman. Christopher Reeve was an actor who became quadriplegic and started the Christopher & Dana Reeve Foundation (CDRF), and Robert Grossman was a neurosurgeon experienced in neurotrauma and a university professor in Houston. NACTN has member investigators at university and military centers in North America and has contributed greatly to the improvement of care, primarily acute care, of patients sustaining traumatic SCI. Its accomplishments are a clinical registry database of >1000 acute SCI patients documenting the care pathways, including complications. NACTN has assessed the effectiveness of treatment, including pharmacotherapy and the role and timing of surgery, and has also identified barriers to early surgery. The principal focus has been on improving neurological recovery. NACTN has trained many SCI practitioners and has collaborated with other SCI networks and organizations internationally to promote the care of SCI patients.
Get full access to this article
View all access options for this article.
References
1.
GrossmanRG, ToupsEG, FrankowskiRF, et al.North American Clinical Trials Network for the Treatment of Spinal Cord Injury: goals and progress. J Neurosurg Spine, 2012; 17(1 Suppl):6–10; doi: 10.3171/2012.4.AOSPINE1294
2.
BlightAR, HsiehJ, CurtA, et al.The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury. Spinal Cord, 2019; 57(5):348–35; doi: 10.1038/s41393-019-0276-2
3.
VallottonK, HuberE, SutterR, et al.Width and neurophysiologic properties of tissue bridges predict recovery after cervical injury. Neurology, 2019; 92(24):e2793–e2802; doi: 10.1212/WNL.0000000000007642
4.
RanganA, JeffersonL, BakerP, et al.Clinical trial networks in orthopaedic surgery. Bone Joint Res, 2014; 3(5):169–74; doi: 10.1302/2046-3758.35.2000265
5.
NemehF, BuchbinderR, HawleyCM, et al.Activities supporting the growth of Clinical Trial Networks in Australia. Trials, 2022; 23(1):81; doi: 10.1186/s13063-021-05974-3
6.
BrackenMB, CollinsWF, FreemanDF, et al.Efficacy of methylprednisolone in acute spinal cord injury. JAMA, 1984; 251(1):45–52; doi: 10.1001/jama.1984.03340250025015
7.
BrackenMB, ShepardMJ, CollinsWF, et al.A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. New Engl J Med, 1990; 322(20):1405–1411; doi: 10.1056/NEJM199005173222001
8.
BrackenMB, ShepardMJ, HolfordTR, et al.Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA, 1997; 277(20):1597–1604; doi:10.1001/jama.1997.03540440031029
GeislerFH, ColemanWP, GriecoG, et al.Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine, 2001; 26(24 Suppl):S68–86; doi: 10.1097/00007632-200112151-00014
11.
BourguignonL, TongB, GeislerF, et al.International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials. BMC Med, 2022; 20(1):225; doi: 10.1186/s12916-022-02395-0
12.
GrassnerL, Garcia-OvejeroD, MachO, et al.A new score based on the International Standards for Neurological Classification of Spinal Cord Injury for Integrative Evaluation of Changes in Sensorimotor Functions. J Neurotrauma, 2022; 39(9–10):613–626; doi: 10.1089/neu.2021.0368
13.
SteevesJ, FawcettJ, TuszynskiM. Report of international clinical trials workshop on spinal cord injury February 20–21, 2004, Vancouver, Canada. Spinal Cord, 2004; 42(10):591–597; doi: 10.1038/sj.sc.3101669
14.
SteevesJD, LammertseD, CurtA, et al.Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord, 2007; 45(3):206–221; doi: 3102008[pii]10.1038/sj.sc.3102008
15.
LammertseD, TuszynskiMH, SteevesJD, et al.Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord, 2007; 45(3):232–242; doi: 3102010[pii]10.1038/sj.sc.3102010
16.
AllenAR.Remarks on the histopathological changes in the spinal cord due to impact. An experimental study. J Nerv Ment Dis, 1914; 41:141–147; doi: 10.1097/00005053-191403000-00002
17.
Allen. AR. Surgery of experimental lesions of the spinal cord equivalent to crush injury of fracture dislocation of the spinal column. A preliminary report. JAMA, 1911; 57:878–880; doi: 10.1001/jama.1911.04260090100008
18.
TarlovIM.Spinal Cord Compression: Mechanisms of Paralysis and Treatment. Thomas: Springfield;, 1957; doi: 10.1302/0301-620X.41B2.446.
19.
GuhaA, TatorCH, EndrenyiL, et al.Decompression of the spinal cord improves recovery after acute experimental spinal cord compression injury. Paraplegia, 1987; 25(4):324–339; doi: 10.1038/sc.1987.61
20.
DolanEJ, TatorCH, EndrenyiL. The value of decompression for acute experimental spinal cord compression injury. J Neurosurg, 1980; 53(6):749–755; doi: 10.3171/jns.1980.53.6.0749
21.
GuhaA, TatorCH, SmithCR, et al.Improvement in post-traumatic spinal cord blood flow with a combination of a calcium channel blocker and a vasopressor. J Trauma, 1989; 29(10):1440–1447; doi: 10.1097/00005373-198910000-00025
22.
FehlingsMG, TatorCH. The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp Neurol, 1995; 132(2):220–228; doi: 10.1016/0014-4886(95)90027-6
23.
NgWP, FehlingsMG, CuddyB, et al.Surgical treatment for acute spinal cord injury study pilot study #2: evaluation of protocol for decompressive surgery within 8 hours of injury. Neurosurg Focus, 1999; 6(1):e3; doi: 10.3171/foc.1999.6.1.4
24.
TatorC, FehlingsM. Clinical Trials in Spinal Cord injury. In: Clinical Trials in Neurologic Practice, Blue Books of Practical Neurology. (Biller J, Bogousslavsky J. eds.) Butterworth-Heinemann: Boston; 2001; pp. 99–120.
25.
TatorCH.Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery, 2006; 59(5):957–987; doi: 10.1227/01.NEU.0000245591.16087.89
26.
TatorCH, FehlingsMG, ThorpeK, et al.Current use and timing of spinal surgery for management of acute spinal surgery for management of acute spinal cord injury in North America: results of a retrospective multicenter study. J Neurosurg, 1999; 91(1 Suppl):12–18; doi: 10.3171/spi.1999.91.1.0012
27.
FehlingsMG, VaccaroA, WilsonJR, et al.Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PloS one, 2012; 7(2):e32037; doi: 10.1371/journal.pone.0032037
28.
MatteiTA. Surgical decompression after spinal cord injury: the earlier, the better! World Neurosurg, 2012; 78(5):384–387; doi: 10.1016/j.wneu.2012.09.004
29.
BrackenMB, ShepardMJ, HellenbrandKG, et al.Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg, 1985; 63(5):704–713; doi: 10.3171/jns.1985.63.5.0704.
30.
MarshallLF, BeckerDP, BowersSA, et al.The National Traumatic Coma Data Bank. Part 1: Design, purpose, goals, and results. J Neurosurg, 1983; 59(2):276–284; doi: 10.3171/jns.1983.59.2.0276
31.
NarayanRK, MichelME, AnsellB, et al.Clinical trials in head injury. J Neurotrauma, 2002; 19(5):503–557; doi: 10.1089/089771502753754037
32.
GoetzCG, StebbinsGT, 3rd, KlawansHL, et al.United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. Prog Brain Res, 1990; 82:611–617; doi: 10.1016/s0079-6123(08)62651-5
33.
NoonanVK, JaglalSB, HumphreysS, et al.Linking spinal cord injury data sets to describe the patient journey following injury: a protocol. Top Spinal Cord Inj Rehabil, 2020; 26(4):232–242; doi: 10.46292/sci20-00016
34.
BadhiwalaJH, WilsonJR, WitiwCD, et al.The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data. Lancet Neurol, 2021; 20(2):117–126, doi: 10.1016/S1474-4422(20)30406-3
35.
BadhiwalaJH, AhujaCS, FehlingsMG. Time is spine: a review of translational advances in spinal cord injury. J Neurosurg Spine, 2018; 30(1):1–18; doi: 10.3171/2018.9.SPINE18682
36.
MulcaheyMJ, JonesLAT, RockholdF, et al.Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. Spinal Cord, 2020; 58(12):1235–124; doi: 10.1038/s41393-020-00547-8
37.
Kalsi-RyanS, BeatonD, CurtA, et al.The Graded Redefined Assessment of Strength Sensibility and Prehension: reliability and validity. J Neurotrauma, 2012; 29(5):905–914; doi: 10.1089/neu.2010.1504
38.
GuestJ, HarropJS, AarabiB, et al.Optimization of the decision-making process for the selection of therapeutics to undergo clinical testing for spinal cord injury in the North American Clinical Trials Network. J Neurosurg Spine, 2012; 17(1 Suppl):94–101; doi: 10.3171/2012.5.AOSPINE1289
39.
SchwartzG, FehlingsMG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg, 2001; 94(2 Suppl):245–256; doi: 10.3171/spi.2001.94.2.0245
40.
GrossmanRG, FehlingsMG, FrankowskiRF, et al.A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma, 2014; 31(3):239–255; doi: 10.1089/neu.2013.2969
41.
FehlingsMG, NakashimaH, NagoshiN, et al.Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord, 2016; 54(1):8–15; doi: 10.1038/sc.2015.95
42.
AarabiB, HarropJS, TatorCH, et al.Predictors of pulmonary complications in blunt traumatic spinal cord injury. J Neurosurg Spine, 2012; 17(1 Suppl):38–45; doi: 10.3171/2012.4.AOSPINE1295
43.
JiangF, JajaBNR, KurpadSN, et al.Acute adverse events after spinal cord injury and their relationship to long-term neurologic and functional outcomes: analysis from the North American Clinical Trials Network for Spinal Cord Injury. Crit Care Med, 2019; 47(11):e854–e862; doi: 10.1097/CCM.0000000000003937
44.
AimettiAA, KirshblumS, CurtA, et al.Natural history of neurological improvement following complete (AIS A) thoracic spinal cord injury across three registries to guide acute clinical trial design and interpretation. Spinal Cord, 2019; 57(9):753–762; doi: 10.1038/s41393-019-0299-8
45.
FingerhutL, WarnerM.Injury Chartbook, Health, United States. National Center for Health Statistics: Hyattsville, MD; 1997.
46.
CashaS, RiceT, StirlingDP, et al.Cerebrospinal fluid biomarkers in human spinal cord injury from a phase II minocycline trial. J Neurotrauma, 2018; 35(16):1918–1928; doi: 10.1089/neu.2018.5899
47.
AustinJW, KangCE, BaumannMD, et al.The effects of intrathecal injection of a hyaluronan-based hydrogel on inflammation, scarring and neurobehavioural outcomes in a rat model of severe spinal cord injury associated with arachnoiditis. Biomaterials, 33(18):4555–4564; doi: S0142-9612(12)00294-3 [pii]10.1016/j.biomaterials.2012.03.022
48.
WilsonJR, TetreaultLA, KwonBK, et al.Timing of decompression in patients with acute spinal cord injury: a systematic review. Global Spine J, 2017; 7(3 Suppl):95S–115S; doi: 10.1177/2192568217701716
